Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are useful for treating a patient suffering from a HCV infection and to pharmaceutical compositions containing such compounds.

Abstract: A device (1) for providing protection for an electrical installation against overvoltages including at least one protection component (2), the device having a first mounting (14) delimiting a first interstitial space (14?) with a dimension fixed by construction that at least partially houses a first conducting element (10) and a second conducting element (11) to make the electrical connection between the first conducting element and the second conducting element, the device also having a second mounting (15) delimiting a second interstitial space (15?) with a dimension fixed by construction that at least partially houses a third conducting element (12) and a fourth conducting element (13) so as to make the electrical connection between the third conducting element and the fourth conducting element.

Abstract: A device (1) for protecting an electrical installation from overvoltages, having at least one protection component (2) and disconnection means (3) capable of changing from a closed configuration to an open configuration, as well as signaling means (5) capable of indicating the configuration of the disconnection means (3). The disconnection means (3) and the signaling means (5) respectively comprise a mobile disconnection element (4) and a mobile signaling element (12) arranged such that, when going from the closed configuration to the open configuration, the mobile disconnection element (4) moves in a rotational movement according to a first trajectory and cooperates with the mobile signaling element (12) to drive the mobile signaling element in rotation along a second trajectory different from the first trajectory.

Abstract: A device for protecting an electrical system against surge voltages, comprising one or more protection components (10), means (20) for disconnecting the protection component (10) and means (30) for visually indicating the state of the component (10), operationally connected to the disconnection means (20) and comprising at least one control part (40) and at least one means (50) for indicating the state of the protection component (10), combined with the control part (40), whereby the relative arrangement of the control part (40) and the disconnection means (20) is such that, when the disconnection means are opened (20), the disconnection means release the control part (40), thereby allowing the control part to move.

Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Abstract: A gas vent valve assembly may be attached or incorporated to a disposable fluid transfer set used with a fluid warmer to administer an infusate to a patient. The gas vent valve assembly has a housing having a fluid inlet, a gas outlet and a fluid outlet. The gas outlet is located at the top of the housing while the fluid outlet is located at the bottom of the housing. The fluid inlet is located at a side lower portion of the housing. Inside the housing is an actuator float that has an upper seal and a lower seal. The dimension of the float relative to the chamber of the housing is such that the float is freely movable within the housing to an upper position whereby its upper seal closes the gas outlet while the fluid outlet is opened, and to a lower position whereby its lower seal closes the fluid outlet and the gas outlet is opened. The movement of the float is dependent on the respective amounts of air and fluid in the housing, and the buoyancy of the float relative to the fluid in the housing.

Abstract: A device (1) for protecting an electrical installation (2) from overvoltages, including at least one protection component (3), and disconnection element (4) capable of ensuring the electrical disconnection of the protection component from the installation by moving from a closed configuration to an open configuration, wherein the device (1) has at least one first fuse element (7) and one second fuse element (8) capable of holding the disconnection element (4) in the closed configuration, and wherein the disconnection element (4) includes at least one first contact surface (4A) and one second contact surface (4B) substantially intersecting with one another and to which the first and second fuse elements respectively adhere when the disconnection element (4) are in the closed configuration, to distribute the stresses exerted on the fuse elements and reinforce the mechanical strength of the disconnection element.

Abstract: The present invention is directed to dental prophylaxis devices that improve portability, maneuverability and aid in retaining clean conditions for use on dental patients, particularly to dental handpieces. The present invention is also directed prophylaxis or prophy angles for use with such handpieces. In general, a dental prophylaxis device includes a handpiece and a prophy angle which includes a driven shaft and a prophy cup attached for rotation thereto. The handpiece generally includes a body which houses a rotational source coupled to an output shaft which couples to the driven shaft in the prophy angle via angled gear interfaces on the output shaft and the driven shaft.

Abstract: The present invention relates to the use of nucleoside derivatives of formula I 1

Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to the use of nucleoside derivatives of formula I 1

Abstract: The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2′-deoxy-2′-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and pharmaceutical compositions of such compounds. The compounds of this invention have potential use as therapeutic agents for the treatment of HCV infections.

Abstract: The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2′-deoxy-2′-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and pharmaceutical compositions of such compounds. The compounds of this invention have potential use as therapeutic agents for the treatment of HCV infections.

Abstract: Thermoplastically processable polyurethanes are produced by the reaction of tolylene diisocyanate, at least one polycaprolactone diol, a low molecular weight diol chain extender and water.

Abstract: Thermoplastic urethane polymer is filled with cross-linked urethane polymer. The presence of the filler has little or no adverse effect on the properties of the thermoplastic urethane polymer.